PASADENA, Calif., May 26, 2021 – Individuals with genetic high cholesterol, heart disease or both, who were infected with COVID-19 had more heart attacks according to new research by the FH Foundation. While previous studies have speculated about poorer outcomes if a person with genetic high … Read More →
Healthcare systems around the world have failed to rescue individuals born with Familial Hypercholesterolemia (FH), even though we have had life-saving therapies for the last 34 years. Without the societal commitment to screen, diagnose, and manage FH, the opportunity to prevent heart disease and … Read More →
How learnings from COVID-19 can be applied to understanding the most destructive pandemic in human history: heart disease.
What is the impact of early diagnosis and appropriate treatment on disease management and longevity for individuals with familial hypercholesterolemia (FH) over the course of 45 years?
I answered this and many other questions in this research letter titled “Life by the Numbers: Living with Familial … Read More →
Large-scale research and genetic studies concur that familial hypercholesterolemia (FH) is a common genetic condition that impacts all races and ethnicities. In fact, it is estimated that 1 in 250 individuals worldwide have FH. That means, each of us reading this FH Foundation blog probably knows … Read More →
Katherine Wilemon, founder and CEO of the FH Foundation, recently authored a paper with researchers from Stanford University that highlighted key differences in care for women with familial hypercholesterolemia (FH). The paper published in Current Atherosclerosis Reports highlights the unique needs … Read More →
So, what are some of the early signs of heart disease? And what should you do if you experience them? My advice, is to recommend that you seek medical attention, if you experience any of the following symptoms:
Chest Pain – often described as tightness, pressure, squeezing or aching beneath … Read More →
The Food and Drug Administration (FDA) approved today a new drug to treat adult and pediatric patients aged 12 years and older with Homozygous Familial Hypercholesterolemia (HoFH), the rare and most severe form of FH.This is welcome news, as individuals with HoFH usually are not able to adequately … Read More →
The Institute for Clinical and Economic Review (ICER) – an organization that produces reports that analyze the cost effectiveness of drugs and other medical services – has highlighted the improved cost-effectiveness of high cholesterol treatments inclisiran and bempedoic acid in patients … Read More →
The FH Foundation is proud to announce our partnership with the CDC Foundation as an inaugural community partner in the “Alliance for Million Hearts Campaign.” The campaign is a new public-private coalition with the nation’s leading organizations and thought leaders to confront the nation’s … Read More →
